Prevalence of Diabetes 15.8 Percent in U.S. Adults From 2021 to 2023
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Nov. 6, 2024 -- The prevalence of diabetes was 15.8 percent among U.S. adults during August 2021 to August 2023, according to a November data brief published by the National Center for Health Statistics.
Jane A. Gwira, M.D., M.P.H., from the National Center for Health Statistics in Hyattsville, Maryland, and colleagues used data from the National Health and Nutrition Examination Survey to examine the prevalence of diagnosed, undiagnosed, and total diabetes (excluding gestational diabetes) among U.S. adults during August 2021 to August 2023.
The researchers found that the prevalence of total diabetes was 15.8 percent, and the prevalence rates of diagnosed and undiagnosed diabetes were 11.3 and 4.5 percent, respectively, among U.S. adults during August 2021 to August 2023. Men had a higher prevalence of total and diagnosed diabetes than women (18.0 and 12.9 percent versus 13.7 and 9.7 percent). With age and with increasing weight status, there was an increase in the prevalence of total, diagnosed, and undiagnosed diabetes. Between 1999-2002 and August 2021 to August 2023, there was an increase in the age-adjusted prevalence of total and diagnosed diabetes.
"Slightly more than one-quarter of adults with diabetes had undiagnosed diabetes," the authors write. "Continued monitoring of both diagnosed and undiagnosed diabetes will provide essential information about the prevalence of diabetes in adults in the United States."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes
FRIDAY, June 20, 2025 -- For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and...
DASH Diet for Diabetes With Low Sodium Reduces BP in Those With Diabetes
WEDNESDAY, June 18, 2025 -- The Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) diet with lower sodium is tied to clinically meaningful blood pressure reduction in...
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.